Search Results

You are looking at 1 - 10 of 258 items for :

  • User-accessible content x
Clear All
Open access

Alessandro Pocai

insulin. Recent work on understanding the physiological function of proglucagon-derived peptides has renewed interest in glucagon-based therapeutics. One of these peptides is glucagon-like peptide-1 (GLP1), which is secreted from the L cells of the

Free access

Zhengu Liu, Violeta Stanojevic, Luke J Brindamour and Joel F Habener

-cells to produce and secrete insulin in response to nutrients (glucose) and shortens their life span ( Grattagliano et al . 2008 , Haas & Biddinger 2009 ). In this study, we report that a nonapeptide, GLP1(28–36)amide, consisting of the C-terminal domain

Free access

Jennifer S ten Kulve, Dick J Veltman, Liselotte van Bloemendaal, Paul F C Groot, Henricus G Ruhé, Frederik Barkhof, Michaela Diamant and Richard G Ijzerman

, Cummings 2013 ), except for glucagon-like peptide-1 (GLP1). GLP1 is a gut-derived hormone, mainly known for its glucose-lowering effects ( Kreymann et al. 1987 , Mojsov et al. 1987 ); however, numerous preclinical and clinical studies have shown that

Free access

Bernardo Nuche-Berenguer, Daniel Lozano, Irene Gutiérrez-Rojas, Paola Moreno, María L Mariñoso, Pedro Esbrit and María L Villanueva-Peñacarrillo

obese subjects ( Zhao et al . 2008 , Buizert et al . 2009 ). It has been reported that the anti-diabetic peptides glucagon-like peptide 1 (GLP-1) and exendin 1–39 amide (Ex-4) show beneficial effects in reducing cholesterol and triglycerides in

Free access

N M Whalley, L E Pritchard, D M Smith and A White

-cells of the intestine with PC1 catalysing the cleavage to yield glucagon-like peptide (GLP)-1 and GLP-2 ( Fig. 1 a). Evidence suggests the tissue-specific processing is due to differential expression of PC1 ( Tucker et al . 1996 ) and PC2 ( Rouille et al

Free access

Guillaume Mabilleau, Marie Pereira and Chantal Chenu

needed, to reach an HbA 1C level of 7% or less. Among the most prescribed drugs, the glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently attracted attention as Glp-1r -knockout animals, and GLP-1-supplemented animals exhibited

Restricted access

Weijuan Shao, Wenjuan Liu, Ping Liang, Zhuolun Song, Odisho Israel, Gerald J Prud’homme, Qinghua Wang and Tianru Jin

homeostasis induced by high fat diet feeding ( Untereiner et al. 2019 ). Sitagliptin is a type 2 diabetes (T2D) therapeutic agent, which prevents degradation of native incretin hormones, including glucagon-like peptide-1 (GLP-1) and gastric inhibitory

Free access

Yolanda Diz-Chaves, Manuel Gil-Lozano, Laura Toba, Juan Fandiño, Hugo Ogando, Lucas C González-Matías and Federico Mallo

and GCs impose a trend towards the development of obesity and diabetes in adulthood. Finally, we consider how the agonists of the GLP-1 receptor (GLP-1R) can interfere with these processes, modulating the activity of the HPA axis, the SNS and the

Free access

Sayaka Akieda-Asai, Paul-Emile Poleni, Kazuya Hasegawa and Yukari Date

( Bjorbaek & Kahn 2004 ). Leptin also inhibits AMP-activated protein kinase (AMPK) activity in the arcuate nucleus and in the paraventricular nucleus of the hypothalamus ( Minokoshi et al . 2004 ). Glucagon-like peptide-1 (GLP1), a gastrointestinal hormone

Restricted access

Akiko Mizokami, Satoru Mukai, Jing Gao, Tomoyo Kawakubo-Yasukochi, Takahito Otani, Hiroshi Takeuchi, Eijiro Jimi and Masato Hirata

et al. 2014 ) or indirectly through stimulation of the secretion of glucagon-like peptide-1 (GLP-1) from intestinal endocrine cells ( Mizokami et al. 2013 , 2014 ). GLP-1 is a member of the incretin family of hormones that are secreted from